今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

甲骨文第四财季营收142.87亿美元 净利润同比下降5%

北京讯 6月12日，甲骨文（ORCL.US）公布了截至2024年5月31日的第四财季财报。财报显示，甲骨文第四财季营收142.87亿美元，同比增长4%；净利润51.54亿美元，同比下降5%。

营收稳健增长

甲骨文第四财季营收142.87亿美元，略高于分析师预期的142.6亿美元。其中，云基础设施（IaaS）业务营收20亿美元，同比增长22%；云平台（PaaS）和应用软件（SaaS）业务营收122.87亿美元，同比增长3%。

云业务持续发力

甲骨文第四财季云业务营收142.87亿美元，同比增长20%，占总营收的比重进一步提升至100%。其中，云基础设施（IaaS）业务营收20亿美元，同比增长22%；云平台（PaaS）和应用软件（SaaS）业务营收122.87亿美元，同比增长3%。

净利润同比下降

甲骨文第四财季净利润51.54亿美元，同比下降5%。净利润下降的主要原因是公司进行了税收调整，导致了一次性费用增加。

总体表现稳健

总体而言，甲骨文第四财季的业绩表现稳健，营收和云业务均保持增长。尽管净利润有所下降，但主要原因是税收调整的一次性费用，并不反映公司的核心经营状况。

以下是一些可以参考的新闻来源：

• 甲骨文第四财季营收142.87亿美元 净利润同比下降5% https://finance.sina.com.cn/stock/usstock/c/2024-06-12/doc-inaynphz7363800.shtml?cre=tianyi&mod=pchp&loc=8&r=0&rfunc=66&tj=cxvertical_pc_hp&tr=12
• 甲骨文(ORCL.US)Q4业绩好于预期盘后大涨近14% https://finance.sina.com.cn/stock/hkstock/ggscyd/2022-06-14/doc-imizirau8295227.shtml
• 不计入一次性项目（不按照美国通用会计准则），甲骨文第四财季调整后总营收同样为118.40亿美元，与上年同期的112.27亿美元相比增长5%，不计入汇率变动的影响为同比增长10%，超出分析师预期。据雅虎财经频道提供的数据显示，18名分析师此前平均预期甲骨文第四财季云授权和现场授权业务营收将达20.9亿美元。 https://m.c114.com.cn/w123-1198903.html

固态硬盘价格连续三个季度出现上涨 但需求增长缓慢

北京讯 6月11日，据业内人士透露，由于存储器厂商为改善盈利而调整供应策略，导致NAND闪存价格连续三个季度出现上涨。不过，由于需求增长缓慢，固态硬盘（SSD）价格涨幅有所放缓。

NAND闪存价格连续三个季度上涨

据悉，由于全球经济形势不确定，存储器厂商为降低库存风险，从2022年下半年开始陆续调整供应策略，减少NAND闪存的产量。这导致NAND闪存价格在过去三个季度持续上涨。

固态硬盘价格涨幅有所放缓